Literature DB >> 12796550

Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies.

Elaine Perry1, Ian McKeith, Clive Ballard.   

Abstract

Butyrylcholinesterase is implicated in the pathology of AD. Selective inhibitors increase acetylcholine and improve cognitive function in animal models. In dementia with Lewy bodies, cholinergic activities are more affected than in AD. The authors report a highly significant association between temporal cortex butyrylcholinesterase activity and the rate of cognitive decline in a prospectively studied, autopsy-confirmed dementia with Lewy bodies series.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12796550     DOI： 10.1212/01.wnl.0000068336.84399.9e

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  14 in total

Review 1.  Rivastigmine in Parkinson's disease dementia: profile report.

Authors:  M Asif A Siddiqui; Antona J Wagstaff
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

2.  Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent.

Authors:  Nigel H Greig; Tadanobu Utsuki; Donald K Ingram; Yue Wang; Giancarlo Pepeu; Carla Scali; Qian-Sheng Yu; Jacek Mamczarz; Harold W Holloway; Tony Giordano; DeMao Chen; Katsutoshi Furukawa; Kumar Sambamurti; Arnold Brossi; Debomoy K Lahiri
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-07       Impact factor: 11.205

3.  Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation.

Authors:  C Holmes; C Ballard; D Lehmann; A David Smith; H Beaumont; I N Day; M Nadeem Khan; S Lovestone; M McCulley; C M Morris; D G Munoz; K O'Brien; C Russ; T Del Ser; D Warden
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

4.  Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study.

Authors:  Carl H Sadowsky; Martin R Farlow; Leone Atkinson; Jennifer Steadman; Barbara Koumaras; Michael Chen; Dario Mirski
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

5.  Association of BDNF and BCHE with Alzheimer's disease: Meta-analysis based on 56 genetic case-control studies of 12,563 cases and 12,622 controls.

Authors:  Huihui Ji; Dongjun Dai; Yunliang Wang; Danjie Jiang; Xingyu Zhou; Peipei Lin; Xiaosui Ji; Jinfeng Li; Yuzheng Zhang; Honglei Yin; Rongrong Chen; Lina Zhang; Mingqing Xu; Shiwei Duan; Qinwen Wang
Journal:  Exp Ther Med       Date:  2015-03-03       Impact factor: 2.447

Review 6.  The significance of the cholinergic system in the brain during aging and in Alzheimer's disease.

Authors:  R Schliebs; T Arendt
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

Review 7.  Rivastigmine: in Parkinson's disease dementia.

Authors:  M Asif A Siddiqui; Antona J Wagstaff
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

8.  Aryl acylamidase activity on acetylcholinesterase is high during early chicken brain development.

Authors:  Rathanam Boopathy; Paul G Layer
Journal:  Protein J       Date:  2004-07       Impact factor: 2.371

9.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07

10.  Is There Any Association Between Neurodegenerative Diseases and Periodontitis? A Systematic Review.

Authors:  María Olimpia Paz Alvarenga; Deborah Ribeiro Frazão; Isabella Gomes de Matos; Leonardo Oliveira Bittencourt; Nathália Carolina Fernandes Fagundes; Cassiano Kuchenbecker Rösing; Lucianne Cople Maia; Rafael Rodrigues Lima
Journal:  Front Aging Neurosci       Date:  2021-05-24       Impact factor: 5.750
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.